Century Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The company has pivoted its iPSC platform to focus on beta islet cell therapy for type 1 diabetes, targeting a large unmet need with a holistic immune evasion strategy and scalable manufacturing innovations. IND submission is planned for late 2025, with initial clinical data expected in 2027.
-
Two lead programs, CNTY-813 for Type 1 Diabetes and CNTY-308 for autoimmune diseases, are advancing toward clinical trials in 2024, both leveraging advanced immune evasion technology. The company aims for a functional cure in diabetes and broad application of iPSC-derived therapies, with a cash runway to Q1 2029.
Fiscal Year 2025
-
The company is advancing iPSC-derived cell therapies for autoimmune diseases, cancer, and type 1 diabetes, with key programs moving toward clinical trials and IND submissions. Alloevasion technology enables immune evasion, supporting scalable therapies. Cash runway extends into Q4 2027.
-
Key programs in iPSC-derived NK and T cell therapies are advancing, with robust alloevasion technology enabling off-the-shelf treatments for autoimmune and B-cell diseases. Clinical and preclinical data show strong efficacy, safety, and persistence, with major data readouts expected this year.
-
Recent strategic transformation has prioritized high-potential iPSC-derived cell therapy programs, leveraging Allo-Evasion™ technology for both immune and non-immune targets. Century 101 is advancing in autoimmune disease trials, while Century 308 is set to enter the clinic next year.
-
Four preclinical programs prioritized, all using advanced Allo-Evasion 5.0 for broad immune protection and scalable iPSC-derived cell therapies. Lead programs target oncology and autoimmune diseases, with manufacturing capacity supporting large-scale, cost-effective production. Strategic partnerships and regulatory engagement are ongoing.
Fiscal Year 2024
-
The company highlighted its iPSC platform's engineerability, reproducibility, and scalability, with promising phase 1 data for CNTY-101 in B-cell malignancies and expansion into autoimmune indications. Preclinical pipeline growth, new engineering advances, and a strong BMS partnership support a robust outlook.
-
The event highlighted advances in iPSC-derived cell therapies, emphasizing Allo-Evasion technology for improved persistence and safety. Interim phase 1 data in lymphoma showed strong safety and efficacy, while new trials target autoimmune diseases with flexible dosing and robust early endpoints.